G1 Therapeutics
G1 Therapeutics developed trilaciclib (Cosela), a CDK4/6 inhibitor given before chemotherapy to protect bone marrow, approved in 2021 for small-cell lung cancer; the company was acquired by Pharmacosmos in 2024.
Overview
G1 Therapeutics, based in Research Triangle Park, North Carolina, developed trilaciclib, an intravenous CDK4/6 inhibitor that briefly halts haematopoietic stem cells before chemotherapy so they are spared its damage. The FDA approved it as Cosela in February 2021 to reduce chemotherapy-induced myelosuppression in extensive-stage small-cell lung cancer; a phase 3 trial in triple-negative breast cancer (PRESERVE 2) did not improve survival. Pharmacosmos, the Danish iron-medicine company, acquired G1 in 2024. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- CompanyBeyondSpring Pharmaceuticals
Shares Neutropenia and the tag ctgov-sponsor.
- CompanySpectrum Pharmaceuticals
Shares Neutropenia and the tag ctgov-sponsor.
- CompanyGenprex
Shares Small-cell lung cancer and the tag ctgov-sponsor.
- CompanyEpicentRx
Shares Small-cell lung cancer and the tag ctgov-sponsor.
- CompanyMabwell (Shanghai) Bioscience
Shares Triple-negative breast cancer (TNBC) and the tag ctgov-sponsor.
- CompanyAlaunos Therapeutics (formerly Ziopharm Oncology)
Shares Small-cell lung cancer and the tag ctgov-sponsor.
- CompanyScancell
Shares Triple-negative breast cancer (TNBC) and the tag ctgov-sponsor.
- CompanyNanjing Leads Biolabs
Shares Triple-negative breast cancer (TNBC) and the tag ctgov-sponsor.